Insights about U.S. Stocks from mix sectors that landed in the Green-Zone in the course of Tuesday’s trade, are depicted underneath:
U.S. Silica Holdings Inc (NYSE:SLCA)’s shares picked up 4.43%, and closed at $33.50, during the last trading session.
U.S. Silica Holdings, Inc. formerly on February 24, declared net revenue of $33.2 million or $0.62 per basic share and $0.61 per diluted share for the fourth quarter ended Dec. 31, 2014 contrast with net revenue of $16.5 million or $0.31 per basic and diluted share for the fourth quarter of 2013. Not including business development expense during the quarter of about $6.5 million or $0.10 per basic share, EPS was $0.72 per basic share. The quarter was also negatively influenced by a meaningful raise in bad debt expense of $6.9 million mostly related to the Corporation’s assessment of a certain customer’s current ability to pay its obligation to the Corporation.
Fourth Quarter 2014 Highlights:
Total Corporation:
Proceed totaled $249.6 million contrast with $149.5 million for the same period last year, an raise of 67%.
Overall tons sold raised to 3.0 million tons, a 43% improvement over the fourth quarter of 2013.
Selling, general and administrative expense for the quarter were greater than predictable and totaled $35.7 million contrast with $14.5 million for the fourth quarter of 2013. The raise in SG&A was due primarily to an $8.7 million raise in compensation expense mostly related to our annual bonus incentive plan, the $6.9 million raise in bad debt expense and a $6.4 million raise in business development expense.
Contribution margin for the quarter was $93.9 million contrast with $48.0 million in the same period of the preceding year.
Adjusted EBITDA was $67.0 million or 27% of proceed as compared to $35.9 million or 24% of proceed for the same period last year.
U.S. Silica Holdings, Inc. produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The corporation offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
Abraxas Petroleum Corp (NASDAQ:AXAS), raised 4.29%, and closed at $ 3.16.
Abraxas Petroleum Corp. formerly on February 23, declared 2014 year end reserves grew 37% over 2013 to 42.4 MMBoe, and also offered first quarter 2015 guidance.
December 31, 2014 Reserves:
As of December 31, 2014, Abraxas’ proved oil and natural gas reserves comprised of about 42.4 MMBoe, a net raise of 11.4 MMBoe, or about 37%, over 2013 year end reserves of 31.0 MMBoe. The majority of the reserve additions came from the Bakken where the Corporation benefited from an upward revision in the type curve and successful downspacing tests in the Middle Bakken and Three Forks. The additional undeveloped locations on the Southern Fault Block at Jourdanton remain unbooked. December 31, 2014 reserves comprised of about 29.4 million barrels of oil, 3.7 million barrels of NGLs and 55.9 billion cubic feet of natural gas. Proved developed producing reserves grew 34% year over year to 17.4 MMBoe and comprised 41% of proved reserves as of December 31, 2014. The present value, using a 10% discount rate, of future net cash flows before revenue taxes of Abraxas’ proved reserves was about $637.4 million, using 2014 average prices of $4.35/mcf of natural gas and $95.28/bbl of oil. The independent reserve engineering firm DeGolyer and MacNaughton prepared a complete engineering analysis on 98.2% of Abraxas’ proved reserves on a Boe basis.
Abraxas Petroleum Corporation, an independent energy corporation, is engaged in the attainment, exploitation, development, and production of oil and gas in the United States and Canada. The corporation operates oil and gas assets in the Rocky Mountain, Permian Basin, and onshore Gulf Coast regions of the United States, in addition to in the province of Alberta, Canada. As of December 31, 2013, its estimated net proved reserves were 31.0 million barrels of oil equivalent. The corporation was founded in 1977 and is based in San Antonio, Texas.
Sequenom, Inc (NASDAQ:SQNM), enhanced 4.24%, and closed at $3.69.
Sequenom Inc. a leading molecular diagnostics corporation, declared it will report financial results for the fourth quarter and full year 2014 after closing of the NASDAQ Global Market on Wednesday, March 4, 2015.
A conference call hosted by William Welch, CEO, and other members of senior administration will take place on Wednesday, March 4, 2015, at 5:00 p.m. EDT (2:00 p.m. PDT) and will be webcast live on the Sequenom Website.
Sequenom Inc. a life sciences corporation, provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets in the United States and internationally. It operates through two segments, Sequenom Center for Molecular Medicine and Sequenom Bioscience. The Sequenom Center for Molecular Medicine segment provides molecular based, laboratory developed tests (LDTs) with a focus principally on prenatal diseases and conditions, and ophthalmological diseases and conditions. Its LDTs comprise MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene RHD LDT, a NIPT to determine the presence or absence of fetal Rhesus D factor; and RetnaGene AMD LDT, a genetic test to predict the risk of a patient with dry or early stage age-related macular degeneration.
BioScrip Inc (NASDAQ:BIOS), rose 4.23%, and closed at $5.42.
BioScrip Inc. declared 2014 fourth quarter financial results. Fourth quarter proceed from ongoing operations was $253.7 million and the net loss from ongoing operations was $61.9 million, or $0.90 per basic and diluted share. Non-GAAP adjusted loss from ongoing operations per basic and diluted share was $0.69.
Fourth Quarter Highlights:
- Total proceed raised by $28.2 million, or 12.5%, as contrast to the preceding year period. Proceed from the Infusion Services segment raised to $239.5 million, reflecting 13.0% growth year-over-year, driven by organic proceed growth;
- Gross profit from ongoing operations was $65.6 million, or 25.9% of proceed, as contrast to $68.2 million, or 30.2% of proceed, in the preceding year period;
- Adjusted EBITDA from ongoing operations was a loss of $30.6 million, primarily reflecting incremental allowance for bad debt expense.
- The Corporation booked an incremental $31.7 million charge to bad debt, an raise of $29.2 million contrast to the preceding year period, bringing the total bad debt expense in 2014 to $79.6 million. The Corporation believes this charge appropriately reserves older account receivables;
- The Corporation implemented an annualized $15 million in formerly identified cost savings projects and identified incremental gross savings of $9 million predictable to be realized in 2015, for a total of $24 million of predictable gross cost savings in the year. Net of investments and expenses to support double digit organic growth and continued improvement of cash collections, the Corporation anticipates realizing a total of $10 million in net cost savings in 2015;
- Cash flow from ongoing operations was positive for the second successive sequential quarter at $2.0 million; and,
- As a result of the continued focus on cash collections, the Corporation has raised monthly average accounts receivable collections from $70.0 million in the first quarter of 2014 to $83.0 million in the fourth quarter of 2014.
BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit administration (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. The Infusion Services segment offers home infusion and respiratory therapy services; and durable medical equipment, products, and services. Its home infusion services comprise the intravenous administration of medications to treat various acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic conditions, cancer, pain, and palliative care.
